Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018159432) MESENCHYMAL STEM CELLS AND PHARMACEUTICAL COMPOSITION
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/159432 International Application No.: PCT/JP2018/006364
Publication Date: 07.09.2018 International Filing Date: 22.02.2018
IPC:
C12N 5/0775 (2010.01) ,A61K 35/28 (2015.01) ,A61P 43/00 (2006.01)
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5
Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
07
Animal cells or tissues
071
Vertebrate cells or tissues, e.g. human cells or tissues
077
Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
0775
Mesenchymal stem cells; Adipose-tissue derived stem cells
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35
Medicinal preparations containing material or reaction products thereof with undetermined constitution
12
Materials from mammals or birds
28
Marrow; Spleen
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
43
Drugs for specific purposes, not provided for in groups A61P1/-A61P41/108
Applicants:
ロート製薬株式会社 ROHTO PHARMACEUTICAL CO., LTD. [JP/JP]; 大阪府大阪市生野区巽西1丁目8番1号 1-8-1, Tatsumi-nishi, Ikuno-ku, Osaka-shi, Osaka 5448666, JP
Inventors:
上野 惟 UENO Yui; JP
野中 秀紀 NONAKA Hidenori; JP
Agent:
特許業務法人 津国 TSUKUNI & ASSOCIATES; 東京都千代田区麹町5-3-1 麹町ビジネスセンター Kojimachi Business Center, 5-3-1, Kojimachi, Chiyoda-ku, Tokyo 1020083, JP
山村 大介 YAMAMURA Daisuke; JP
森田 慶子 MORITA Yoshiko; JP
Priority Data:
2017-04080703.03.2017JP
Title (EN) MESENCHYMAL STEM CELLS AND PHARMACEUTICAL COMPOSITION
(FR) CELLULE SOUCHE MÉSENCHYMATEUSE, ET COMPOSITION PHARMACEUTIQUE
(JA) 間葉系幹細胞及び医薬組成物
Abstract:
(EN) The purpose of the present invention is to provide a mesenchymal stem cell that is highly safe when used as a medicinal product. The present invention is a mesenchymal stem cell characterized in that the tissue factor (TF) is expressed at low levels. Furthermore, the present invention includes a mesenchymal stem cell characterized in that at least one integrin gene selected from the group consisting of ITGA11, ITGA1, ITGB5, ITGBL1, ITGB1 and ITGAV is expressed at low levels. Furthermore, the present invention includes a mesenchymal stem cell characterized in that at least one integrin gene selected from the group consisting of ITGA4, ITGA9, ITGA7, and ITGA10 is expressed at high levels. It is preferable that the mesenchymal stem cell is allogeneic and is derived from a fatty tissue. The present invention also includes a pharmaceutical composition containing the mesenchymal stem cell.
(FR) L’invention a pour objet de fournir une cellule souche mésenchymateuse présentant une sécurité élevée lorsqu’elle est mise en œuvre en tant que produit pharmaceutique. En outre, l’invention concerne une cellule souche mésenchymateuse qui est caractéristique en ce que l’expression d’un facteur tissulaire (TF) est faible. De plus, l’invention inclut une cellule souche mésenchymateuse qui est caractéristique en ce que l’expression d’au moins une sorte de gène d’intégrine choisie dans un groupe constitué de ITGA11, ITGA1, ITGB5, ITGBL1, ITGB1 et ITGAV, est faible. L’invention inclut également une cellule souche mésenchymateuse qui est caractéristique en ce que l’expression d’au moins une sorte de gène d’intégrine choisie dans un groupe constitué de ITGA4, ITGA9, ITGA7 et ITGA10, est élevée. De préférence, ladite cellule souche mésenchymateuse est d’origine xénogénique, et est dérivée de tissus adipeux. Enfin, l’invention inclut une composition pharmaceutique qui comprend ladite cellule souche mésenchymateuse.
(JA) 本発明は、医薬品として用いる際に、安全性の高い間葉系幹細胞を提供することを目的とする。 本発明は、組織因子(TF)が低発現であることを特徴とする、間葉系幹細胞である。また、本発明は、ITGA11、ITGA1、ITGB5、ITGBL1、ITGB1及びITGAVからなる群より選択される少なくとも一種のインテグリン遺伝子が低発現であることを特徴とする間葉系幹細胞も含む。さらに、ITGA4、ITGA9、ITGA7及びITGA10からなる群より選択される少なくとも一種のインテグリン遺伝子が高発現であることを特徴とする間葉系幹細胞も含む。上記間葉系幹細胞は他家由来であること、脂肪組織由来であることが好ましい。本発明は、上記間葉系幹細胞を含有する医薬組成物も含む。
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Japanese (JA)
Filing Language: Japanese (JA)